Characterization of the Molecular Mechanism of the Bone-Anabolic Activity of Carfilzomib in Multiple Myeloma

Carfilzomib, the next generation of proteasome inhibitor, may increase osteoblast-related markers in patients with multiple myeloma, but the molecular mechanism of its effect on mesenchymal stem cell differentiation to osteoblasts remains unknown. Herein, we demonstrated that carfilzomib significant...

Descripción completa

Detalles Bibliográficos
Autores principales: Hu, Bo, Chen, Yu, Usmani, Saad Z., Ye, Shiqiao, Qiang, Wei, Papanikolaou, Xenofon, Heuck, Christoph J., Yaccoby, Shmuel, Williams, Bart O., Van Rhee, Frits, Barlogie, Bart, Epstein, Joshua, Qiang, Ya-Wei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2013
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3774816/
https://www.ncbi.nlm.nih.gov/pubmed/24066119
http://dx.doi.org/10.1371/journal.pone.0074191

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3774816/
https://www.ncbi.nlm.nih.gov/pubmed/24066119
http://dx.doi.org/10.1371/journal.pone.0074191

Ejemplares similares